NASS

Gyeonggi, South Korea
Gyeonggi, South Korea
SEARCH FILTERS
Time filter
Source Type

News Article | May 4, 2017
Site: www.thedrinksbusiness.com

According to figures released by Hop Growers of America, US acreage of hops in 2012 stood at 29,683. In 2016 this figure stood at 52,963, having increased by 17% from 45,238 in 2015, with an additional 5,185 acres expected to take the total to 58,148 acres in 2017. “To put it into perspective, the US acres added in the last five years is larger than the total acreage of any other hop-growing country in the world, outside of our own and Germany, the two largest hop-producing countries,” said Ann George, the executive Director of Hop Growers of America (HGA). “Further, our estimated 2017 acreage increase (5,185 acres – a 9.8 % growth) by itself is larger than other individual countries’ total acreage outside of the U.S., Germany, and the Czech Republic.” The US has been the largest hop producer since 2015, when it over took Germany’s total hop acreage for the first time. The third largest producer is the Czech Republic with 11,800 acres, followed by China with 4,942 acres. While the US hop market is far more stable than in past years, benefitting from high demand and a diversified customer base, the HGA has urged producers to remain “responsible and realistic” when contracting hops to ensure supply and demand are kept in balance. “When a brewery has a hop variety they depend on and is crucial to their operation, it is dangerous to rely solely on the spot market,” said Patrick Smith, vice president of hop grower B.T. Loftus Ranches, Inc. “Growers rely on forward contracts to plan their acreage for many years out into the future. However, contracting an excessive amount above their needs is not wise either as brewers can be left with expensive hops that they may not be able to sell to other brewers. Over-contracting can also lead to a surplus in the market which tends to discourage future investments in productive capacity and leads to increasing market instability. A surplus can be just as disruptive to the market as a shortage.” In addition to acreage increasing in the US, stocks left in storage with brewers, growers and merchants are increasing as well, with the USDA NASS March 2017 report showing a 9% increase in 2016, and a 7.5% increase the year before that. “It is important to note that the amount of hop stocks which dealers are holding has increased,” added George. “Merchants are taking on increased risk as the proportion of stocks held in their possession has risen over 10% in the past three years. The stock report is another key signal to the market and we will continue to monitor these data trends.”


News Article | May 8, 2017
Site: www.marketwired.com

Company to Conduct Cadaver Lab and Work Shop Lecture with Leading Spine Surgeon and Advisory Board Member Dr. Vik Kapoor ATLANTA, GA--(Marketwired - May 8, 2017) - Medovex Corp. ( : MDVX), a developer of medical technology products, today announced that it will attend The NSpine Main Conference June 12-15, 2017 in London. The NSpine Main Conference takes place every two years to provide the latest knowledge for spine healthcare professionals. Growing in strength with each meeting, NSpine provides ascendant medical professionals with the supplementary material they need to forge best practice in their careers. All areas of the meeting are covered comprehensively with parallel sessions being held to allow delegates to tailor their learning experience to their specific needs. Boasting cadaver sessions, workshops, seminars, lunch symposiums and an exhaustive list of lectures and exhibitions by leading practitioners and innovative companies, NSpine endeavours to cater to its delegates' academic pursuit. NSpine 2017 will take place in London, UK on June 12-15 and was developed in collaboration with the European Spine Journal, BioSpine, NASS and EANS. Manfred Sablowski, Senior Vice President Global Sales & Marketing of Medovex, stated, "The NSpine show will be an excellent meeting venue to meet with key surgeons while we continue to prepare for our launch of the DenerveX System." Sablowski went on to say: "The UK market is very important to us since it will be a leading country for our initial entry into Europe once we receive the CE Mark. The Company will conduct both a cadaver lab and a workshop session with advisory board member and leading spine surgeon Dr. Vik Kapoor." The Company's patented DenerveX™ System is not yet commercially available in the EU and the U.S. The DenerveX System is designed to provide longer lasting relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain. The DenerveX System consists of the DenerveX Device Kit, containing a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. DenerveX is not yet CE marked or FDA cleared. Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com. Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.


News Article | April 17, 2017
Site: www.prweb.com

NYC-based PIRA Energy Group reports that gasoline imports into Latin America to stay strong in 2Q17. In the U.S., light products lead inventory lower. In Japan, crude stocks build while demand eases seasonally. Specifically, PIRA’s analysis of the oil market fundamentals has revealed the following: Asian refiners have been buying more crude from the Atlantic Basin due to narrower Brent-Dubai price spreads and declining freight rates. Asian net exports of key light products will ease as demand growth is expected to outpace incremental refinery runs in the region in 2017. Product exporters to Australia are fighting for market share. Asian LPG imports will grow more slowly this year due to moderating demand growth. Asian refining margins will remain generally healthy in 2017. The price of gas supplied by Russian state-owned Gazprom at Germany’s border climbed 14% in February IMF data show. Day-ahead gas on the UK’s National Balancing Point fell 20% in February, according to broker data compiled by Bloomberg. Gazprom, which supplies about a third of Europe’s gas, sees its prices recovering from a 12-year low in 2016. Most of the exporter’s contracts have an oil link, usually with a delay of six to nine months, while some also have minimum and maximum prices indexed to market rates. Gazprom plans to ship a record volume to its biggest market for a second year even as more liquefied natural gas may come to Europe this summer. It sees European gas demand rising about 5% in 2017, deputy head Alexander Medvedev said last week in an interview. PIRA’s U.S. Power Storage Outlook reviews the latest trends in U.S. storage project installations, policy and market changes, and technology and cost developments, providing an updated market penetration forecast through 2024. PIRA has upgraded its post-2018 penetration forecast for SPP, ISO-NE, and NYISO, which will be most impacted by FERC’s recent proposal, along with other updates. Beyond the FERC proposal, PIRA does not see Trump administration policies changing our outlook, though tax reform, FERC appointments, and an infrastructure package are areas to watch in the coming months. The report also reviews the state of long-duration storage systems, including pumped-hydro storage (with around 30 U.S. projects in the development pipeline), compressed air, gravitational storage, thermal storage, flow batteries, and hydrogen systems. EU Council Weighs in on Post-2020 Carbon Market Reforms, With Short-Lived Price Gains EU Carbon Allowance (EUA) prices rose on the EU Council’s support for post-2020 market reforms and a stronger oversupply measures at their Feb 28th meeting, but the price gain was short-lived. The reform package could still change in the upcoming “Trialogue” negotiations, but the reforms currently on the table will have only a limited near- to mid-term impact on market oversupply. With the exception of a compliance-related rise in April, we maintain a generally flat view for EUAs in 2017. The possibility of price gains from positive Trialogue talks is balanced by a poor fundamentals situation, with auction volumes remaining high and declining power sector EUA demand. With warmer weather dominating in February, electric loads fell nearly 4% year-on-year and coal burn was up only negligibly as compared with last year’s levels. As winter supply risks have fallen off and demand is close to entering the shoulder period, it is unlikely that coal prices will be able to break out of their downward trend and push higher until summer arrives. U.S. ethanol prices bounced late in the week ending March 10. RIN prices rebounded after plummeting the previous week. January exports of fuel grade ethanol climbed after shipments to Brazil reached a five year high and cargoes to Asia more than doubled. European ethanol values plunged as more supply became available. A deeper dive into the Trump budget released Thursday morning showed that the hefty $4.7 billion proposed cut to the USDA budget would not affect crop insurance although that remains a hot button topic. Cuts in USDA county offices and statistical capabilities at NASS were specifically mentioned, along with rural water infrastructure. The county office cut was previously mentioned by the Obama Administration with no result. Going to be a long and tough fight amongst factions on the USDA budget in our opinion. Fed Paints Rate Hike in Positive Light; Better Data from U.S. / China At the policy meeting, the U.S. central bank did two things. First, as expected, it hiked the policy interest rate by 0.25%. Second, it sent a constructive message about the economic growth and monetary policy outlook via its communication tools. Specifically, policymakers assigned a good grade to the economy’s current performance; and they also made certain to communicate that the Fed has not become more hawkish compared to three months ago. In China, data releases for January / February were solid, indicating that the economic growth rate probably strengthened from the fourth quarter of last year. Tanker rates are off to a slow start in 2017 and are expected to weaken further due to OPEC and non-OPEC production cuts and excessive vessel supply growth. Suezmax markets were a notable exception with rates recovering in February from rock-bottom levels in January. But the respite may be short as we approach the seasonally weak second quarter. Gasoline Imports into Latin America to Stay Strong in 2Q17 Gasoline imports into Latin America are expected to stay strong in 2Q17. However, gasoline and diesel demands are forecast to be modestly lower year-on-year. Mexican and Venezuelan gasoline demand is projected lower year-on-year while Brazil’s is flat. Furthermore, Brazilian spark ignition fuel demand is set to fall in 2017 with petroleum gasoline demand to be flat as ethanol market share is projected to decline. PIRA expects regional refining crude runs in 2Q17 to be lower year-on-year. Winter-like weather conditions finally returned — catching many off guard — with some parts of the U.S., primarily in the Northeast and Midwest, facing the coldest temperatures of the year. The belated return of cold air from the Arctic put an end to worries that U.S. storage levels would swell to 2.2+ TCF, which was weighing heavily on price expectations throughout February. The end of such concerns is allowing attention to shift back onto the other issues at work that have tightened weather-adjusted balances and kept gas prices at ~$3/MMBtu throughout much of the heating season. French Nuclear Availability Low in March, in Spite of ASN Clearance French nuclear availability remains at a multi-year low point for this time of the year (48.3 GW, or the lowest in the past six years), but the French nuclear regulator ASN has issued a press release on March 15 confirming the authorization to restart 12 of the reactors affected by the steam generator anomaly. It is interesting to note that the previous minimum availability for nuclear in March was set in 2014 (50.8 GW), i.e. 36 months ago. As a result of the generation cycles adopted by EDF, similar availability patterns are likely to recur every 3 years because of the length of the two maintenance cycles. The increased availability to 50.3 GW next month, the highest of the past six years for April, and high levels of availability through to June, based on REMIT data, recalls the pattern seen in 2014, when availability was also at a record high. Coal market prices diverged considerably this week, with FOB Newcastle prices rising considerably across the forward curve, while FOB Richards Bay and CIF ARA prices pushed lower. Physical tightness surrounding China was the driving force behind the rise in FOB Newcastle prices in PIRA’s view. PIRA’s belief that China’s domestic coal demand strength was maintained into 2017 was confirmed this week, with the National Bureau of Statistics (NBS) releasing strong electricity generation figures for the January/February aggregate. Despite some strength in WTI prices, falling demand and a decline in Henry Hub prices lowered U.S. NGL prices. Mont Belvieu ethane futures fell by 5% to 22¢/gal, while propane futures fell by 6% to 59¢/gal. Normal butane futures declined by 5% to 75¢/gal and isobutane similarly declined by 5% to 77¢/gal. Natural gasoline registered no week-on-week decline and was flat at $1.10/gal. There was noted rotation in the domestic vs. international equity markets this past week. The broad U.S. market was little changed, with housing being the best performing sector. Energy basically matched market performance. International indices were all broadly higher and did very well as noted by the strength in the world, ex-US, tracking index. Performance was led by emerging markets, emerging Asia, and China. U.S. ethanol production rose 23 MB/D to a 5-week high 1,045 MB/D the week ending March 10, the sixth highest output ever reported. PADD II stocks climbed to a record 8.4 million barrels despite a decline in total U.S. inventories to 22.8 million barrels. Ethanol-blended gasoline manufacture increased to 9,049 MB/D from 8,697 MB/D as total gasoline production increased. An extremely slow end to the trading week received a jolt on Friday afternoon as the weekly Commitment of Traders report reflect surprisingly large selling by the Funds in commodities generally, and grains/oilseeds specifically. The 900 million combined bushels of corn, soybeans, SRW, and HRW sold by the Funds was one of the heaviest single weeks in our memory. Combined with large bean oil liquidation, and some meal, Funds sold a record 207.5K contracts during the reporting week which included a WASDE but did not include the Fed’s rate hike. Overall commercial stocks declined by 7.8 million barrels on the latest week, led by a steep 9.8 million barrel drop in the four major products. Crude stocks were down just 0.2 million barrels, although Cushing added 2.1 million barrels, given the temporary closure of the Seaway Pipeline. Imports of crude were down to 7.4 MMB/D, 750 MB/D less than the previous week. Refinery runs were flat week-on-week. With planned downtime anticipated to fall in the coming weeks, refinery runs will be increasing. Gazprom’s Proposal to Alter Contracts May Have Unintended Consequences Gazprom has offered to settle their longstanding disputes with European antitrust authorities, theoretically in exchange for greater access to European markets and for their bigger ambitions to deliver more gas volumes through a second Nordstream pipe and the Turkstream pipeline. Gazprom offered to remedy issues with 8 Eastern European nations that represent around 15% of Russia’s pipeline gas sales, the biggest of whom is Poland that represents 4.5% of Russia’s total pipeline sales. On the surface, it may seem like Gazprom is sacrificing these sales for the hope of bigger ones when OPAL capacity is freed up and their new pipeline projects are fully operational. However, there seems to be some space for Gazprom to charge similar or even higher prices than before. Stress Remains Low as Fed Rate Hike Announced The S&P 500 was modestly changed on the week, but other indicators, such as the Russell 2000, posted more noticeable gains. Volatility (VIX) was lower, while the prices of high yield debt (HYG), and emerging market debt (EMB) moved higher. The Fed raised its target fed funds rate 25 basis points, while long-term U.S. government rates also tended to move higher, along with mortgage interest rates. Japanese crude runs continue to ease on the week, while crude imports rose sharply and crude stocks built 5.7 million barrels. Finished product stocks drew 1.2 million barrels, with much of the decline being in naphtha. Aggregate major product demand continued to decline seasonally. Gasoline and gasoil demands were lower. Gasoline stocks drew slightly, while gasoil stocks built moderately. Kerosene demand rose marginally, but with much lower yield, and the stock draw rate accelerated. As Australia positions itself to become the world’s largest supplier of LNG, long simmering concerns about domestic supply availability for the key consuming southeast regions within the country have erupted in recent weeks to threaten the short-term viability of export growth from the recently commissioned Queensland export projects in the northeast. At midmonth, March looks to be 2% colder than the 10-year normal for the three major OECD markets, with a composite net oil-heat demand effect of -41 MB/D. The markets are 6% warmer than the 30-year-normal. An explosion struck Syncrude’s 350 MB/D Mildred Lake upgrading site on March 14. A 48 MB/D naphtha hydrotreater as well as piping from the hydrogen plant were damaged. Reports indicate that it could take two months for these units to be repaired and return to full service. Until then, modified production of lower quality, high sulfur syncrude is expected. The Mildred Lake upgrading plant has more than one train, meaning the temporary loss of the hydrotreating facility will not result in a complete shutdown. Expect Syncrude differentials to remain tight during the outage. 75 MB/D “Hidden” Demand Growth in 2017 Due to New Facilities Infrastructure PIRA sees “hidden” demand associated with the start-up of new petroleum/petrochemical facilities and the Myanmar/China pipeline. 1.5-1.7 MMB/D of new refining capacity and 8-9 MMT/A of ethylene capacity are expected to start up in 2017. These new facilities will require oil for infrastructure needs, such as feed tankage and pipeline line fill. This will add roughly 75 MB/D to 2017 demand. PIRA's latest update of major country Asian product demand indicates that year-on-year growth in our latest snapshot slowed to 556 MB/D, vs. 1,157 MB/D last month. Data actuals cover the three month period Dec-Feb. for China and India, while Japan, Taiwan, and Korea pick up data Nov-Jan. Much of the slowing was anticipated and relates to timing issues with regard to the Chinese New Year and India’s removal of “small denomination rupee bills” from circulation. The information above is part of PIRA Energy Group's weekly Energy Market Recap - which alerts readers to PIRA’s current analysis of energy markets around the world as well as the key economic and political factors driving those markets. To read PIRA’s Market Recap first, subscribe to PIRA Perspectives here. Click here for additional information on PIRA’s global energy commodity market research services.


BELGRADE, Mont., May 16, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced it has entered into a licensing agreement with Sites Medical LLC, for utilization of their proprietary OsteoSync™ Ti technology, a best-in-class porous titanium scaffold. "We are very excited to work with Sites Medical," said Carl O'Connell, CEO of Xtant Medical. "As market dynamics shift towards emerging titanium technologies, Sites Medical’s OsteoSync Ti technology places us firmly at the forefront of this trend.  This technology exhibits great synergy with our entire line of spinal implants further enhancing the value of this relationship as well as Xtant’s potential impact in its core market." "We are thrilled to be partnering with Xtant Medical, a company with a rich history of innovation in the spine field," said Greg Stalcup, President/CEO of Sites Medical. "We look forward to working with the Xtant team to combine our respective technologies to deliver a new generation of high performance, high value products to the market." OsteoSync Ti technology is a highly porous titanium scaffold designed to meet the needs of today’s patients from both clinical and economic standpoints. Its high friction coefficient ensures high initial implant stability and its open pore geometry and micro-texturing facilitate superior bone ingrowth. Preclinical testing has demonstrated bone attachment strength nearly twice that of titanium plasma spray and approximately seven times that of PEEK material at the 5-week follow up period, a performance differential that can impact clinical outcomes, especially in spinal fusion patients. OsteoSync Ti technology has also been engineered to reduce the potential for abrasion debris generation during implant insertion, offering an additional measure of safety for the patient. The material is manufactured using highly innovative methods and offers substantial value in today’s cost-conscious healthcare environment. Utilizing Q2 Metrics data, Xtant Medical estimates the total addressable US market for its technologies that can utilize OsteoSync Ti at $2.5B with a 5 year CAGR approaching 4.75%. Xtant Medical’s first devices to utilize the technology will be featured at this year's NASS annual meeting to be held on October 25-28 in Orlando, FL. Xtant Medical Holdings, Inc. (NYSE MKT:XTNT) develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com. Sites Medical has recognized the shift in healthcare reimbursement paradigms and is entirely focused on Value-Driven Innovation in orthopedics. With its suite of proprietary orthopedic implant technologies and manufacturing process improvements, Sites aims to deliver improved clinical outcomes and reduced cost to all stakeholders. SITES can further serve the needs of its OEM partners through its Concept-to-Launch capability, where we conduct all necessary R&D activity and use state-of-the-art manufacturing equipment and techniques to deliver the highest quality product. Additional information about the company can be found at www.sitesmedical.com. This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability to comply with covenants in the Company’s senior credit facility and to make deferred interest payments; the ability to maintain sufficient liquidity to fund operations; the ability to remain listed on the NYSE MKT; the ability to obtain financing on reasonable terms; the ability to increase revenue; the ability to continue as a going concern; the ability to maintain sufficient liquidity to fund operations; the ability to achieve expected results; the ability to remain competitive; government regulations; the ability to innovate and develop new products; the ability to obtain donor cadavers for products; the ability to engage and retain qualified technical personnel and members of the Company’s management team; the availability of Company facilities; government and third-party coverage and reimbursement for Company products; the ability to obtain regulatory approvals; the ability to successfully integrate recent and future business combinations or acquisitions; the ability to use net operating loss carry-forwards to offset future taxable income; the ability to deduct all or a portion of the interest payments on the notes for U.S. federal income tax purposes; the ability to service Company debt; product liability claims and other litigation to which we may be subjected; product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights; infringement and ownership of intellectual property; the ability to remain accredited with the American Association of Tissue Banks; influence by Company management; the ability to pay dividends; and the ability to issue preferred stock; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.


News Article | February 15, 2017
Site: www.prweb.com

Early clinical results presented by surgeons at the 2016 annual meeting of the North American Spine Society (NASS)1 demonstrate high fusion rates at 6 months and beneficial clinical outcomes, for patients in the majority of cases, when PEEK-OPTIMA™ HA Enhanced is used for interbody-fusion devices. The implantable high-performance polymer, from Invibio Biomaterial Solutions, uniquely combines PEEK-OPTIMA, the principal PEEK-based biomaterial with over 15 years of proven history in clinical use, and hydroxyapatite (HA), a well-known osteoconductive material that enhances bone apposition, and is fully integrated. Previous studies by Invibio have highlighted that enhancing bone apposition on all surfaces of an interbody-fusion device may offer better integration and improved potential for spinal fusion. “The findings on first clinical cases for PEEK-OPTIMA HA Enhanced presented at the NASS 2016 annual meeting are demonstrating the Invibio goal of providing solutions that have the potential to improve clinical outcomes and advance bone apposition in interbody-fusion procedures2,” said John Devine, Invibio Medical Business Director. “In addition, the results presented confirm that the partnerships we have forged with device manufacturers and surgeons are pioneering approaches that are leading to positive results for patients.” During NASS, Timothy Bassett, MD, of SouthEastern Spine Specialists, Tuscaloosa, AL, presented his ‘Early Clinical Experience with a PEEK-OPTIMA HA Enhanced Device for Lumbar Fusion’. The 1-2 level TLIF (Transforaminal Lumbar Interbody Fusion) procedure utilized the EVOS HA Device, from Cutting Edge Spine, intended for use in skeletally mature patients with Degenerative Disc Disease (DDD) of the lumbar spine, plus autograft bone with posterior instrumentation. No biologics were used in this series of nine patients. The clinical results were evaluated for pain on the Visual Analogue Scale (VAS), opiate usage, neurological function, re-operations and complications. Fusion results were evaluated using anteroposterior (AP) and lateral X-rays at six weeks and 12 weeks, and a CT scan at six months. Dr Bassett concluded, “Very rapid visible bone fusion occurred in the interbody region in six weeks, according to plain radiographs, with correspondingly good clinical results including no neurologic consequences beyond 6 weeks, no implant migrations, no subsidence, and no pseudoarthroses. More importantly, 9/10 fusions were definitively solid on 6 month CT scan with autograft bone, despite some challenging patients. The one that didn’t show complete fusion was progressing to fusion and used one pack of tobacco daily, both pre- and post-operative, contributing to the fusion challenge. Brad Prybis, MD at Carrollton Orthopaedic Clinic, Carrollton, GA, assessed use of the Talos®-C (HA) Cervical Interbody Fusion Device, from Meditech Spine, in patients who underwent 2-3 level anterior cervical discectomy and fusion (ACDF). Clinical (pain and neurological function) and radiographic outcomes were assessed at six months post-operatively. Arm pain was resolved in all 8 patients; in 5/8 patients neck pain was resolved and improved in 7/8 patients. Furthermore, all 8 patients demonstrated improved neurological function, with residual numbness in 3/8, and residual weakness in 1/8 patients. 17/17 levels were fused 6 months post-operatively. Commenting on the findings, Dr Prybis said, “The Talos-C (HA), a next-generation interbody-fusion device made from PEEK-OPTIMA HA Enhanced polymer, provided clinical and radiographic results as good as or better than traditional PEEK interbody devices, with consistently good outcomes at early time points we are looking forward to the results of further clinical studies.” PEEK-OPTIMA HA Enhanced biomaterial offers all the clinical advantages of PEEK-OPTIMA Natural including a modulus similar to cortical bone, reduced stress shielding and artifact-free imaging that allows for clear fusion assessment. Developed by Invibio, a leading provider of biomaterial solutions, this innovative high performance polymer for spinal fusion implants eliminates the extra processing time and expense of alternative bone on-growth technologies, such as coatings. Implant devices made of the novel PEEK-OPTIMA HA Enhanced have already been cleared by regulatory bodies in both the US (FDA 510(k) clearance) and Europe (CE mark approval). For more information about PEEK-OPTIMA HA Enhanced, please visit http://www.invibiospine.com 2. Study evaluated the in vivo response to PEEK-OPTIMA Natural, PEEK-OPTIMA HA Enhanced and allograft in a cervical spine fusion model in sheep. Data are on file at Invibio. This has not been correlated with human clinical experience. The case study data and testimonials presented here have been provided by practicing orthopedic surgeons. Their views and experiences are their own and do not necessarily reflect those of others. “Invibio” disclaims any liabilities or loss in connection with the information herein. INVIBIO™, PEEK-OPTIMA™, INVIBIO BIOMATERIAL SOLUTIONS™ are trademarks of Victrex plc or its group companies. About Invibio Biomaterial Solutions Invibio, a Victrex plc company, is a global leader in providing high performance biomaterial solutions to medical device manufacturers. The company provides PEEK-OPTIMA™ polymers, advanced technical research and support and manufacturing of components for spine, trauma and orthopaedic medical segments for the development of long implantable medical devices. Today, Invibio’s PEEK-OPTIMA™ polymers are used in more than five million implanted devices worldwide. About Victrex Victrex, headquartered in the UK, is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years’ experience, we are delivering leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at http://www.victrexplc.com


Provides Physical Medicine Rehabilitation Services to Patients in the South Cobb Area including Non-surgical Spine and Functional Medicine ​​​OrthoAtlanta is pleased to welcome board-certified physiatrist, Deitrick L. Cox, M.D., to its orthopedic and sports medicine practice in Austell, bringing expertise in physical medicine and rehabilitation (PM&R) to patients in the greater South Cobb area including Austell, Lithia Springs, Mableton, and Smyrna. Dr. Cox provides non-surgical orthopedic care, including non-surgical spine, musculoskeletal medicine and functional medicine to patients suffering muscular, nerve, joint, and tendon injuries. Dr. Cox’s specialty areas of interest include precision-based treatments such as fluoroscopic-guided interventional spinal injections, including, but not limited to, epidural and facet injections, radiofrequency neurotomy, spiral neuromodulation, sacroiliac joint injections, and hip injections. Dr. Cox is also skilled at ultrasound-guided peripheral joint injections, regenerative medicine, electrodiagnostic medicine / electromyography (EMG), and myofascial trigger point injections. Dr. Cox believes in partnering with his patients to develop treatment plans to significantly reduce, if not eliminate, pain and optimize physical function. As expressed by Dr. Cox, “I seek to maintain the perfect balance between teaching and treating when serving patients. My philosophy of care includes listening to the patient, educating the patient, and collaborating with the patient to develop the best treatment plan for them.” Prior to joining OrthoAtlanta, Dr. Cox had his own company providing procedure-based physiatric and pain management procedures and services to orthopedic, physical medicine and pain management practices within the greater Atlanta area. “We are excited to welcome Dr. Deitrick Cox to OrthoAtlanta Austell to provide non-surgical patient care,” stated OrthoAtlanta Medical Director, Dr. Michael Behr. “Dr. Cox combines a passion for orthopedics, physics, and procedure-based treatment plans that help restore patient functionality to return them to the things they love doing.” Dr. Deitrick Cox graduated from Amherst College, Amherst, MA, completing both a Bachelor of Science degree in Religion and pre-medical studies. Awarded a merit-based medical scholarship, Dr. Cox received his Doctor of Medicine degree at Morehouse School of Medicine in Atlanta, GA. He completed his Internship at Harvard Medical School, Cambridge Health Alliance, in Cambridge, MA and medical residency in Physical Medicine and Rehabilitation at Emory University in Atlanta, GA. Medical professionals influencing Dr. Cox’s decision to pursue a medical career and specialty in physiatry include orthopedic surgeon, J. Mandume Kerina of Leesburg, Florida, and PM&R physicians, Dr. Rosalind Bass and Dr. Lisa Merritt. Dr. Cox is a member of the American Academy of Physical Medicine and Rehabilitation, the National Medical Association and the North American Spine Society (NASS). Dr. Cox is a certified provider with the United States Department of Labor (DOL), Office of Federal Workers’ Compensation, and can accept both Federal and non-government occupational and work-related injury cases as well as personal injury cases. Dr. Cox and his wife have a three-year old son and another child on the way. He enjoys travel and sports including football, basketball and track & field. Appointments with Dr. Deitrick Cox may be requested at OrthoAtlanta Austell, 770-944-3303. About OrthoAtlanta OrthoAtlanta is one of the largest orthopaedic and sports medicine practices in the greater Atlanta, Georgia area. With 39 physicians serving in 12 offices, the physician-owned practice is dedicated to providing the highest level of patient care for injury or deformity of muscles, joints, bones and spine. OrthoAtlanta offers convenient accessibility to a full range of musculoskeletal surgeons, specialists and patient services including on-site physical therapy, pain management care, six MRI imaging centers and workers’ compensation coordination. OrthoAtlanta Surgery Centers in Austell and Fayetteville provide cost-effective, same-day surgical procedures in an accredited outpatient center. Comprehensive operative and non-operative musculoskeletal care and expertise includes sports medicine, arthroscopic surgery, hip replacement, knee replacement, neck and spine surgery, elbow and shoulder surgery, foot and ankle surgery, pain management, arthritis treatment, general orthopedics, work related injuries and acute orthopaedic urgent care.  Learn more at www.OrthoAtlanta.com. For additional information, please contact Pat Prosser, Public Relations Manager, at OrthoAtlanta, 678-996-7254, or via email pprosser@OrthoAtlanta.com.


News Article | February 15, 2017
Site: www.marketwired.com

ATLANTA, GA--(Marketwired - Feb 15, 2017) - Medovex Corp. ( : MDVX), a developer of medical technology products, today announced that the Company successfully completed its final CE Mark audit meeting. The review of the Company's DenerveX™ System was conducted February 7-9, 2017 by LNE/GMED, a French-based Notified Body firm. This audit is required to demonstrate compliance with the regulatory requirements to achieve CE Mark approval. Patrick Kullmann, Medovex President and COO, stated, "We're very pleased to have completed our certification audit of the DenerveX System February 7-9, 2017 at the Company's Atlanta based offices. Our in-house development team, along with several representatives from our world-class suppliers and consultants, contributed extensively during this process due to their vast expertise in R&D, manufacturing, electro-surgery, regulatory, quality, and sterilization processes." Kullmann further stated, "Upon successfully completing this audit, the CE certificate would generally be expected to be issued paving the way to the future launch of the DenerveX System in the EU and other countries which accept the CE Mark." Previously on January 3, 2017, the Company announced it had successfully received certification of compliance for its DenerveX System from SGS S.A. a Swiss based multinational testing and certification firm. Compliance testing included electrical safety testing for US, Canada and the European Union. Prior to that on November 3, 2016, the Company announced that it held a successful cadaver lab during NASS 2016. Medical advisory board members Martin Deeg, MD from Stuttgart, Germany, Vik Kapoor, MD from Manchester, England, as well as Gabriel Davila, MD from Colombia, Latin America, highlighted the DenerveX System. Thirty spine surgeons from Europe and Latin America attended the lab, both experiencing and using the device. Jarrett Gorlin, Medovex CEO, commented, "I'm very proud of our team and how they prepared for and handled this important event. Together, we have spent countless hours in anticipation of meeting with representatives of LNE/GMED. Although a date has not been provided for the anticipated receipt of the CE certificate or the launch of the product, we believe we remain well on our way to completing the final regulatory step in the process of achieving CE Marking." The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power Generator, both designed to be less invasive with faster recovery time than current surgical treatment options, and is expected to provide for a longer lasting treatment solution while offering potential savings to the health care system. DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available. About Medovex Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com Safe Harbor Statement Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.


News Article | February 21, 2017
Site: www.marketwired.com

Recent Completion of Final CE Mark Audit and Financing with Insider Participation Positions Company for 2017 ATLANTA, GA--(Marketwired - Feb 21, 2017) - Medovex Corp. ( : MDVX), a developer of medical technology products, today provided the following corporate update. On February 15th, 2017, the Company announced that it had successfully completed its final CE Mark audit meeting. The review of the Company's DenerveX™ System was conducted February 7-9, 2017 by LNE/GMED, a French-based Notified Body firm. This audit is required to demonstrate compliance with the regulatory requirements to achieve CE Mark approval. Patrick Kullmann, Medovex President and COO, stated, "Upon successfully completing this audit, the CE certificate would generally be expected to be issued paving the way to the future launch of the DenerveX System in the EU and other countries which accept the CE Mark." On February 9, 2017, Medovex Corporation announced it had entered into a unit purchase agreement with selected accredited investors. Pursuant to the terms of the agreement, the Company sold an aggregate of 2,905,770 shares and 1,452,885 warrants for gross proceeds of $3,022,000. Each warrant has an initial exercise price of $1.50 per share, subject to adjustment, and is initially exercisable for a period of five years from the date of issuance. Certain officers and directors of Medovex participated in the financing. In conjunction with the closing of the transaction, the Company's previously issued $1,150,000 of senior secured promissory notes has been converted to 165,864 shares of Common Stock and 9399 shares of Series A Preferred Stock and warrants on the same terms as the other investors. Each share of Series A Preferred Stock is convertible into 100 shares of common stock and effectively has the same price of $1.04 per share of Common Stock. In addition to the recent financing transaction, in a transaction filed with the SEC on a Form 8k on December 6, 2016, insiders Jesse Crowne, Steve Gorlin and a third party, completed the purchase of 571,429 shares of the Company's common stock at above then market pricing of $1.75 per share, such that the Company received an aggregate of $1,000,000. On January 3, 2017, the Company announced it had successfully received certification of compliance for its DenerveX System from SGS S.A. a Swiss based multinational testing and certification firm. Compliance testing included electrical safety testing for US, Canada and the European Union. Prior to that on November 3, 2016, the Company announced that it held a successful cadaver lab during NASS 2016. Medical advisory board members Martin Deeg, MD from Stuttgart, Germany, Vik Kapoor, MD from Manchester, England, as well as Gabriel Davila, MD from Colombia, Latin America, highlighted the DenerveX System. Thirty spine surgeons from Europe and Latin America attended the lab, both experiencing and using the device. Jarrett Gorlin, Medovex CEO, commented, "Design, development and commercialization of our flagship patented DenerveX System has been years in the making. It was designed by surgeons for surgeons to be less invasive with faster recovery time than current surgical treatment options, and is designed to provide for a longer lasting treatment solution while offering potential savings to the health care system. We are pleased with the recent completion of the final CE Mark audit meeting conducted February 7-9, 2017 by LNE/GMED, a French-based Notified Body firm." Gorlin concluded, "My personal commitment is no better evidenced than by my recent insider purchases as filed in recent Form 4 filings made with the SEC. In addition, both our Co-founder and VP of Business Development have too made recent insider purchases. I believe it important that we lead by example putting our own money where our mouth is. Recent filings memorializing our own actions affirm our collective commitment and belief in both our team and the opportunity." The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power Generator. DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available. Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.


ATLANTA, GA--(Marketwired - Feb 27, 2017) -  Medovex Corp. ( : MDVX), a developer of medical technology products, today announced that on Friday, February 24, 2017, the Company filed a Form 8K with the Securities and Exchange Commission affirmatively stating its current compliance with NASDAQ's stockholder equity requirement. From the 8K, "The Company affirmatively states that as of the date of this Current Report on Form 8-K, that it has stockholders' equity in excess of $2,500,000 based on the culmination of the aforementioned transactions." On February 21, 2017, the Company provided the following corporate update. On February 15th, 2017, the Company announced that it had successfully completed its final CE Mark audit meeting. The review of the Company's DenerveX™ System was conducted February 7-9, 2017 by LNE/GMED, a French-based Notified Body firm. This audit is required to demonstrate compliance with the regulatory requirements to achieve CE Mark approval. On February 9, 2017, Medovex Corporation announced it had entered into a unit purchase agreement with selected accredited investors. Pursuant to the terms of the agreement, the Company sold an aggregate of 2,905,770 shares and 1,452,885 warrants for gross proceeds of $3,022,000. Each warrant has an initial exercise price of $1.50 per share, subject to adjustment, and is initially exercisable for a period of five years from the date of issuance. Certain officers and directors of Medovex participated in the financing. In conjunction with the closing of the transaction, the Company's previously issued $1,150,000 of senior secured promissory notes has been converted to 165,864 shares of Common Stock and 9399 shares of Series A Preferred Stock and warrants on the same terms as the other investors. Each share of Series A Preferred Stock is convertible into 100 shares of common stock and effectively has the same price of $1.04 per share of Common Stock. In addition to the recent financing transaction, in a transaction filed with the SEC on a Form 8k on December 6, 2016, insiders Jesse Crowne, Steve Gorlin and a third party, completed the purchase of 571,429 shares of the Company's common stock at above then market pricing of $1.75 per share, such that the Company received an aggregate of $1,000,000. On January 3, 2017, the Company announced it had successfully received certification of compliance for its DenerveX System from SGS S.A., a Swiss based multinational testing and certification firm. Compliance testing included electrical safety testing for US, Canada and the European Union. Prior to that on November 3, 2016, the Company announced that it held a successful cadaver lab during NASS 2016. Medical advisory board members Martin Deeg, MD from Stuttgart, Germany, Vik Kapoor, MD from Manchester, England, as well as Gabriel Davila, MD from Colombia, Latin America, highlighted the DenerveX System. Thirty spine surgeons from Europe and Latin America attended the lab, both experiencing and using the device. The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power Generator. DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available. About Medovex Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com Safe Harbor Statement Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.


News Article | February 15, 2017
Site: www.marketwired.com

WASHINGTON, DC--(Marketwired - February 15, 2017) - The American Land Title Association (ALTA), the national trade association of the land title insurance and real estate settlement industry, sent a letter to the National Association of Secretaries of State (NASS) offering support of efforts to promote the understanding of remote electronic notarizations. In the letter, ALTA offered eight suggestions to help guide the development of clear statutes, regulations and standard practices that authorize and recognize remote electronic notarization. The guidance is necessary to give certainty that remote and video notarizations will be accepted as valid transactions by county recorders, state courts and bankruptcy trustees. "The title insurance and settlement industry seeks assurance that a remotely electronically notarized document will receive the same legal certainty, and provide effective constructive notice, under state law as a traditional, wet-signed, face-to-face, personal appearance notarization," said Michelle Korsmo, ALTA's chief executive officer. "Though states have long accepted traditional notarizations conducted in other states, it is currently unclear as to whether remote electronic notarizations will receive the same treatment." ALTA believes the following elements should be included in remote electronic notarization statutes: For more, you may download ALTA's letter. The American Land Title Association, founded in 1907, is the national trade association representing more than 6,200 title insurance companies, title and settlement agents, independent abstracters, title searchers, and real estate attorneys. With offices throughout the United States, ALTA members conduct title searches, examinations, closings, and issue title insurance that helps protect the property rights of millions of American homebuyers every year.

Loading NASS collaborators
Loading NASS collaborators